Individually calibrated predictors become collectively miscalibrated under Brier-optimal strategic responses with positive belief correlations, but VCG aggregation restores dominant-strategy incentive compatibility and near-optimal performance.
Combining probability forecasts
4 Pith papers cite this work. Polarity classification is still indexing.
4
Pith papers citing it
representative citing papers
The Double Folding Test of Unimodality resolves systematic failures of the original FTU on Dirac and Gaussian mixtures and enhances multimodality detection.
Introduces surrogate regret, gain, and efficiency measures plus AIPW estimators to evaluate the decision-making value of surrogates for learning budget-constrained individualized treatment rules.
A weighted K-means plus decision-tree pipeline learns multi-action policies from observational data and is applied to HCV treatment choices for HIV co-infected patients, finding a high-clearance subgroup and potential cost savings of CAN$3.6-4.9 million.
citing papers explorer
-
When Individually Calibrated Models Become Collectively Miscalibrated
Individually calibrated predictors become collectively miscalibrated under Brier-optimal strategic responses with positive belief correlations, but VCG aggregation restores dominant-strategy incentive compatibility and near-optimal performance.
-
A Note on the Folding Test of Unimodality: limitation and improved alternative
The Double Folding Test of Unimodality resolves systematic failures of the original FTU on Dirac and Gaussian mixtures and enhances multimodality detection.
-
Evaluating Surrogates in Individualized Treatment Rules
Introduces surrogate regret, gain, and efficiency measures plus AIPW estimators to evaluate the decision-making value of surrogates for learning budget-constrained individualized treatment rules.
-
Policy Learning with Observational Data: The Case of Hepatitis C Treatment for HIV/HCV Co-Infected Patients
A weighted K-means plus decision-tree pipeline learns multi-action policies from observational data and is applied to HCV treatment choices for HIV co-infected patients, finding a high-clearance subgroup and potential cost savings of CAN$3.6-4.9 million.